Phase Ib/II Study of Carboplatin + M6620 + Avelumab in PARPi-resistant Ovarian Cancer
Status:
Completed
Trial end date:
2019-11-06
Target enrollment:
Participant gender:
Summary
The study was to evaluate the efficacy and safety of avelumab in combination with M6620 +
carboplatin in participants with PARPi-resistant, recurrent, platinum sensitive ovarian,
primary peritoneal, or fallopian tube cancer.